Antibody Hit Generation and Screening Market
完整報告名稱與涵蓋範圍
Antibody Hit Generation and Screening Market Size, Share & Trends Analysis Distribution By Application (Cancer, Autoimmune Diseases, Infectious Diseases), Technologies (Hit Generation, Phage Display, Yeast Display, Ribosome Display, B-Cell Hybridoma Technology, Computational Tools, Screening), Antibody Type And Segment Forecasts, 2024-2031
報告摘要
The Antibody Hit Generation and Screening Market is positioned for steady expansion, with a projected CAGR of 9.78% from 2024 to 2031.
At its core, Antibody Hit Generation and Screening pertains to a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specif. Stakeholders across the healthcare landscape are surgingly turning to these solutions to meet contemporary demands.
Market momentum is fueled by surging requirement advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold pronounced shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and surging investment in the sector.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Antibody Hit Generation and Screening Market Snapshot
Chapter 4. Global Antibody Hit Generation and Screening Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Application Estimates & Trend Analysis
5.1. by Application & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
5.2.1. Cancer
5.2.2. Autoimmune diseases
5.2.3. Infectious diseases
Chapter 6. Market Segmentation 2: by Technologies Estimates & Trend Analysis
6.1. by Technologies & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technologies:
6.2.1. Hit Generation
6.2.2. Phage display
6.2.3. Yeast display
6.2.4. Ribosome display
6.2.5. B-cell hybridoma technology
6.2.6. Computational tools
6.2.7. Screening
Chapter 7. Market Segmentation 3: by Antibody Type Estimates & Trend Analysis
7.1. by Antibody Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Antibody Type:
7.2.1. Humanized Antibody
7.2.2. Human Antibody
7.2.3. Chimeric Antibody
7.2.4. Murine Antibody
Chapter 8. Antibody Hit Generation and Screening Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.1.2. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.1.3. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.1.4. North America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.2.2. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.2.3. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.2.4. Europe Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.3.2. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.3.3. Asia-Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.3.4. Asia Pacific Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.4. Latin America
8.4.1. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.4.2. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.4.3. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.4.4. Latin America Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
8.5.2. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Technologies, 2024-2031
8.5.3. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by Antibody Type, 2024-2031
8.5.4. Middle East & Africa Antibody Hit Generation and Screening Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. F. Hoffmann-La Roche Ltd.
9.2.2. AbbVie
9.2.3. Pfizer
9.2.4. AstraZeneca
9.2.5. Novartis
9.2.6. Eli Lilly
9.2.7. WuXi AppTec
9.2.8. Charles River Laboratories
9.2.9. Syngenta
9.2.10. BioLegend
9.2.11. Creative Biolabs
9.2.12. Eurofins CDMO
9.2.13. AbCellera
9.2.14. MorphoSys
9.2.15. Evelo Biosciences
9.2.16. Icos Therapeutics
9.2.17. Argenx
9.2.18. Kymab
9.2.19. Alnylam Pharmaceuticals
9.2.20. SAb Biotherapeutics
9.2.21. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們